Lynda Charters

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

The novel system converts light into electrical signals to stimulate retinal cells.

Strategies for treatment intervals, drug selection, and patient expectations.

Panel examines drug mechanisms, patient factors, and strategies to optimize results.

The grading scales were compiled with the goals of achieving conciseness and the ability to provide clear drug-dose-modification recommendations compared with the previous ocular CTCAE scale.

In the study, authors investigated the natural history of GA lesion incidence rates and analyzed potential risk factors for faster incidence of GA lesions.

This retrospective cohort study used a large US administrative claims database to identify patients with a diagnosis of seborrheic dermatitis from January 1, 2016, through June 30, 2022.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

Cases show improved clarity, astigmatism masking, and versatility in complex eyes.

Earlier use of SLT, sustained-release drug delivery, and MIGS is reframing glaucoma care.

Roundtable discussion explores surgical and sustained-release options.

A study reveals that systemic chemotherapy significantly reduces mortality in retinoblastoma, while targeted treatments lower enucleation rates.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk

AMD treatment may become unrecognizable as gene therapies evolve.

While the injuries associated with other similar sports, such as tennis, badminton, and racquetball have been investigated in many studies, no epidemiologic studies have specifically focused on the incidence of ocular injuries that occur in pickleball

In this murine model of glaucoma, SPG302 was administered daily to 3-month-old mice for 8 weeks.

As ophthalmic technologies move at supersonic speed, AI and gene therapy take center stage.

Explore groundbreaking advancements in eye care from the 2000s, including LASIK innovations, anti-VEGF treatments, and enhanced imaging technologies.

Explore the groundbreaking advancements in ophthalmic technology from the 1980s and 1990s, including excimer lasers, LASIK, and innovative imaging techniques.

From lasers to lenses, the 1970s redefined vision care through breakthroughs in surgery, imaging, and therapeutics.

A recent study uncovers a novel biomarker for retinal vascular diseases, highlighting the significance of intermittent capillary perfusion in monitoring treatment efficacy.

Maximizing treatment based on GA location, lesion progression, and morphologic retinal changes.

Join the American Academy of Ophthalmology's annual meeting for cutting-edge insights, networking, and engaging events from October 17-20 in Orlando.